ArticleRSC advances2021
A new pH/NIR responsive theranostic agent for magnetic resonance imaging guided synergistic therapy.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- A review of combined imaging and therapeutic applications based on MNMs.Frontiers in chemistry · 2025Review
- Activatable photothermal agents with target-initiated large spectral separation for highly effective reduction of side effects.Chemical science · 2022Article
- Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New nano-reagents with diagnostic imaging and therapeutic functions are very important for precision medicine against cancer. In this work, a new nanotheraontic agent for magnetic resonance imaging (MRI) guided combined photothermal therapy (PTT) and chemotherapy was constructed based on polydopamine (PDA) functionalized copper ferrite nanospheres (PDA@CFNs). The high relaxivity makes it possible for PDA@CFNs to become a promising MRI contrast agent, providing necessary and exhaustive information for tumor diagnosis. In addition, because both CFNs and PDA have strong near-infrared (NIR) absorption, PDA@CFNs exhibit excellent photothermal performance. Highly effective tumor ablation is achieved in a mouse model through PTT and pH/NIR triggered on-demand chemotherapy. These findings reveal that constructing smart pH/NIR responsive multifunctional theranostic agents is a feasible strategy for precision cancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.